A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC).

Options in metastatic urothelial cancer after first-line therapy

“…One phase II study of 23 patients demonstrated an ORR of 5%, TTP of 4.2 months, and OS of 9.9 months. Significant toxicity issues were noted with a 10% rate of febrile neutropenia and death [10]. With minimal clinical activity and high toxicity rates, cabazitaxel is unlikely to be a favorable option to move forward in this patient population.…”